AI Digital Biomarkers Deployed
Annovis partnered with NeuroRPM to deploy an AI‑powered digital biomarker platform in a Parkinson's disease study—using continuous patient data streams and analytics to assess therapy response. The deployment shows how real‑world digital endpoints can be validated and scaled. (globenewswire.com)
ANVS‑25002 is registered on ClinicalTrials.gov as an open‑label long‑term safety study that began January 9, 2026, with an estimated enrollment of 500 participants and primary completion projected for September 2029 and study completion in November 2029. (clinicaltrials.gov) The protocol calls for 36 months of treatment across 25 U.S. clinical sites as part of an Open‑Label Extension testing buntanetap, the investigational oral therapy from Annovis Bio. (markets.ft.com) NeuroRPM’s FDA‑cleared, AI‑enabled wearable platform will use the Apple Watch to passively collect movement sensor data and algorithmically quantify core motor features—bradykinesia, tremor and dyskinesia—for continuous, real‑world measurement. (markets.businessinsider.com) The trial documentation and company releases state eligible participants may opt into the NeuroRPM monitoring program to complement scheduled clinic visits, and multiple outlets report the ANVS‑25002 study has enrolled about 90 patients to date toward the ≈500 target. (markets.businessinsider.com) (biospace.com) Annovis is pairing the wearable program with a minimally invasive skin‑biopsy assay to detect misfolded phosphorylated α‑synuclein, and the Syn‑One/JAMA data cited for skin detection report cutaneous p‑α‑synuclein in 92.7% of patients with clinical Parkinson’s disease. (annovisbio.com) (jamanetwork.com) Annovis describes buntanetap as its lead investigational candidate for neurodegenerative disorders and quoted company leadership regarding the value of AI‑driven, continuous monitoring to augment traditional outcome measures in the study. (markets.ft.com)
